Novartis’ breast cancer drug cuts risk of death by 19 percent after six years, data shows

LONDON: Swiss drugmaker Novartis’ drug Kisqali helped extend survival for women with a form of high-risk, early-stage breast cancer, cutting their risk of death by 19 percent after six years, according to trial data presented at the European Society for Medical Oncology congress in Madrid on Friday. At six years, 91.9 percent of women who received ⁠Kisqali and hormone therapy were ⁠alive compared with 89.7 percent of those who received hormone therapy alone. The survival gap grew from 1.2 per

NewsBeagle is a discovery engine. We show the headline, a short source-supplied summary and clear attribution. The complete reporting remains with the publisher.